A Phase 3 interventional study of Cabergoline and Gliclazide in Diabetes, sponsored by Sherief Abd-Elsalam. Status unknown at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2018-08-27.
Sponsored by Sherief Abd-Elsalam · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Diabetes Mellitus with a site in Egypt — 32 open to participants now, 41 under way, 2 of them phase 3. Diabetes Mellitus · Egypt.
Among the 146 studies in Diabetes Mellitus with a site in Egypt, this one is the 46th largest by planned enrollment of the 101 interventional ones that give a count, is one of 8 that started in 2017, is one of 10 in phase 3, and was the 27th registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →32 of the 146 studies in Diabetes Mellitus with a site in Egypt are open now. Recruiting first, the newest first:
Badr University · Sites in Egypt
Ages 36–58
Alexandria University · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 35–45 · Men only
Sara A Belal · Sites in Egypt
Ages 25+
Al-Azhar University · Sites in Egypt
Ages 18–75
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 12 · Phase 4 17
First in 2006; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 60 across the 101 interventional studies, 108 across the 45 observational. Of the 86 that completed or were terminated, 8 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 146 have an industry lead sponsor. The 10 most frequent:
Sherief Abd-Elsalam is the lead sponsor of 50 studies on the registry; 23 are open to participants now.
Sherief Abd-Elsalam has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
7 of the studies in Diabetes Mellitus with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496593Ain Shams UniversityTotal Intravenous and Balanced Anesthesia in Diabetic Patients Undergoing Video-Assisted Thoracoscopy | 2026-12-01 |
| NCT07306884Assiut UniversityNeurophysiological, Autonomic, and Sonographic Assessment of Diabetic Peripheral Neuropathy | 2027-01 |
| NCT07817277Al-Azhar UniversityHair Changes in Females With Type 2 Diabetes Clinical and Trichoscopic Examination | 2027-01-01 |
| NCT07928752Badr UniversityEffects of Adjunctive Melatonin Gel in Type II Diabetics With Stage III-IV Periodontitis | 2027-03 |
| NCT07204782Assiut UniversityCardiovascular Disease CVD Constitutes a Significant Health Challenge for Individuals With Type 2 Diabetes Mellitus T2DM, Affecting Approximately 32% of This Population and Contributing Significantly to Global Mortality.Visceral Adipose Tissue VAT Accumulation Has Been Recognize | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 146 studies in Diabetes Mellitus with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of the glycemic efficacy of cabergoline on diabetic patients
Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agentswith novel mechanisms of action is highly desirable. Cabergoline, a long acting D2 agonist, is expected to play a role in the glycemic control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
Drug: Cabergoline
gliclazide (60-120 mg) once daily
Drug: Gliclazide
Placebo
cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
gliclazide (60-120 mg)
The level of fasting and post prandial BG level
Fasting and post prandial BG level will be measured after 4 months
Time frame: 4 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2017 (actual). Primary completion is estimated for Oct 2020, 36 months after the start.
Of 63 non-industry phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 79. This study's planned 36 months is below that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabergoline
Sherief Abd-Elsalam